Tag: Columvi LBCL treatment

Home / Columvi LBCL treatment

Categories

Glofitamab-gxbm is approved by FDA for selected relapsed or refractory large B-cell lymphomas

July 2023: The Food and Drug Administration gave accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (...
columvi-lbcl-treatment

We Are Online! Chat With Us!
Scan the code